Compare BSVN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSVN | RCKT |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | United States | United States |
| Employees | N/A | 299 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.6M | 428.6M |
| IPO Year | 2018 | N/A |
| Metric | BSVN | RCKT |
|---|---|---|
| Price | $43.73 | $3.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $53.33 | $29.12 |
| AVG Volume (30 Days) | 16.2K | ★ 1.9M |
| Earning Date | 01-15-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | ★ 19.43 | N/A |
| EPS | ★ 4.54 | N/A |
| Revenue | ★ $95,710,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.23 | N/A |
| P/E Ratio | $9.50 | ★ N/A |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $32.49 | $2.19 |
| 52 Week High | $50.26 | $11.45 |
| Indicator | BSVN | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 55.32 |
| Support Level | $42.07 | $3.47 |
| Resistance Level | $42.99 | $3.98 |
| Average True Range (ATR) | 0.99 | 0.22 |
| MACD | 0.18 | 0.02 |
| Stochastic Oscillator | 95.60 | 55.80 |
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.